Reichmuth Pilatus
Successful thanks to innovation and value culture?
With Reichmuth Pilatus, we have been investing in innovative Swiss small companies for almost 25 years – a true success story. In this video you can see how we got there, on what we put emphasize on with respect to stock selection and how we generally manage this particular portfolio.
«The ‘human’ factor plays a central role in the selection of stocks; this is true for the company’s management, its board of directors and other stakeholders.»
Research, Head of Investment Policy
PLEASE DO NOT HESITATE TO CONTACT US FOR A CONSULTATION
News
Liability instead of rescue – an appeal from private bankers to politicians
As part of a broad-based initiative to strengthen personal responsibility in the banking sector, a guest article entitled “Haften statt retten” (Liability instead of rescue) was published in the Neue Zürcher Zeitung (NZZ) on September 1, 2025. The article was written by Christian Bidermann, partner at Rahn & Bodmer and Jürg Staub, general partner at Reichmuth & Co.
Is the Swiss currency rocket taking off?
Switzerland is sitting on a ticking currency time bomb: the Swiss franc. What has been regarded as a sign of stability and solidity for years could prove highly explosive in the event of a new global economic shock. While the Swiss Confederation shines as a safe haven with one of the lowest debt ratios in the world and a credible monetary stability policy pursued by the SNB, it is precisely this status that threatens to become a challenge.
Swiss pharmaceutical industry facing political headwinds
The pharmaceutical industry is currently high on Donald Trump’s list of priorities. He wants more production and jobs in the US, as well as lower drug prices. As a means of exerting pressure, he is threatening to impose price caps and introduce tariffs on drugs. These goals are, of course, contradictory, which is causing even more uncertainty.